Early response to treatment with Glivec® detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor;PET 18F-FDG en la detección temprana de la respuesta al tratamiento con Glivec® en paciente con tumor del estroma gastrointestinal

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 2, 2008, Pages 112-117

  Delgado Bolton, R C ^a,b   Ortega Candil, A ^b   Perez Castejon M J ^b   Garcerant, M ^c   Cabrera Martin M N ^b   Lapena Gutierrez L ^a   Carreras Delgado, J L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Instituto PET Focuscan   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

18F FDG; Gastrointestinal stromal tumor; GIST; Glivec ; PET

Indexed keywords

DIAZEPAM; FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CASE REPORT; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; REMISSION; TREATMENT RESPONSE; MIDDLE AGED; SCINTISCANNING; TIME;

ANTINEOPLASTIC AGENTS; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 42549100975     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13117192     Document Type: Article

References (17)

1. Reddy MP, Reddy P, Lilien DL. F-18 FDG PET in gastrointestinal stromal tumor. Clin Nucl Med. 2003;28:677-9.
2. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
3. Delgado Bolton RC, Pérez Castejón MJ, Carreras Delgado JL. Aportación de la PET, PET-TAC y TAC en GIST: Actualización. Oncología. 2007;30:138-47.
4. Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockish A, Kühl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging. 2006;31:25-35.
5. Simó Perdigó M, García Garzón JR, Soler Peter M, Pérez Moure G, López Gandul S, Lomeña Caballero FJ. Utilidad de la PET con FDG en el estudio de estadificación inicial, recurrencia y respuesta al tratamiento con imatinib (Glivec) en pacientes diagnosticados de un tumor del estroma intestinal. Rev Esp Med Nucl. 2006;25:80-8.
6. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-20.
7. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging using Fluorine-18-FDG. J Nucl Med. 1998;39:1302-5.
8. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357-65.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
10. World Health Organization. WHO Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization; 1979. Offset Publication No. 48.
11. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433-8.
12. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol. 2004;183:1619-28.
13. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression [abstract]. J Clin Oncol. 2006;24 Suppl:9506.
14. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9.
15. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-4.
16. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-62.
17. García-González J, Sánchez Salmón A, Areses Manrique C, León Mateos L, Barandela Salgado J, López López R. Utilidad de la FDG-PET en la evaluación precoz de la eficacia de imatinib (Glivec) en el tratamiento de tumores del estroma gastrointestinal. Rev Esp Med Nucl. 2007;26:100-2.